Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 26, 2018
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
[ Mon, Mar 26th 2018
] - WOPRAI
Fri, March 23, 2018
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
[ Fri, Mar 23rd 2018
] - WOPRAI
Alex Arfaei Maintained (ABBV) at Sell with Decreased Target to $80 on, Mar 23rd, 2018
Published on 2024-10-26 04:01:12 -
Alex Arfaei of BMO Capital, Maintained "AbbVie Inc." (ABBV) at Sell with Decreased Target from $95 to $80 on, Mar 23rd, 2018.
Alex has made no other calls on ABBV in the last 4 months.
There are 2 other peers that have a rating on ABBV. Out of the 2 peers that are also analyzing ABBV, 1 agrees with Alex's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Geoffrey Porges of "Leerink Swann" Downgraded from Buy to Hold on, Monday, January 29th, 2018
This is the rating of the analyst that currently disagrees with Alex
- David Toung of "Argus Research" Maintained at Strong Buy with Increased Target to $145 on, Friday, February 2nd, 2018